Anti-CD15 monoclonal antibody
Pre-made anti-CD15 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to CD15/FUT4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP0027-Ab-1/ GM-Tg-hg-IP0027-Ab-2 | Anti-Human CD15/FUT4 monoclonal antibody | Human |
GM-Tg-rg-IP0027-Ab-1/ GM-Tg-rg-IP0027-Ab-2 | Anti-Rat CD15/FUT4 monoclonal antibody | Rat |
GM-Tg-mg-IP0027-Ab-1/ GM-Tg-mg-IP0027-Ab-2 | Anti-Mouse CD15/FUT4 monoclonal antibody | Mouse |
GM-Tg-cynog-IP0027-Ab-1/ GM-Tg-cynog-IP0027-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD15/FUT4 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP0027-Ab-1/ GM-Tg-felg-IP0027-Ab-2 | Anti-Feline CD15/FUT4 monoclonal antibody | Feline |
GM-Tg-cang-IP0027-Ab-1/ GM-Tg-cang-IP0027-Ab-2 | Anti-Canine CD15/FUT4 monoclonal antibody | Canine |
GM-Tg-bovg-IP0027-Ab-1/ GM-Tg-bovg-IP0027-Ab-2 | Anti-Bovine CD15/FUT4 monoclonal antibody | Bovine |
GM-Tg-equg-IP0027-Ab-1/ GM-Tg-equg-IP0027-Ab-2 | Anti-Equine CD15/FUT4 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP0027-Ab-1/ GM-Tg-hg-IP0027-Ab-2; GM-Tg-rg-IP0027-Ab-1/ GM-Tg-rg-IP0027-Ab-2; GM-Tg-mg-IP0027-Ab-1/ GM-Tg-mg-IP0027-Ab-2; GM-Tg-cynog-IP0027-Ab-1/ GM-Tg-cynog-IP0027-Ab-2; GM-Tg-felg-IP0027-Ab-1/ GM-Tg-felg-IP0027-Ab-2; GM-Tg-cang-IP0027-Ab-1/ GM-Tg-cang-IP0027-Ab-2; GM-Tg-bovg-IP0027-Ab-1/ GM-Tg-bovg-IP0027-Ab-2; GM-Tg-equg-IP0027-Ab-1/ GM-Tg-equg-IP0027-Ab-2 |
Products Name | Anti-CD15/FUT4 monoclonal antibody |
Format | mab |
Target Name | CD15 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-CD15 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-INN-1011 | Pre-Made Technetium (99Mtc) Fanolesomab Biosimilar, Radiolabelled Antibody, Anti-Cd15 Antibody: Anti-ELFT/FCT3A/FUC-TIV/FUTIV/LeX/SSEA-1 therapeutic antibody |
Target Antigen | GM-Tg-g-IP0027-Ag-1 | Recombinant multi-species FUT4/ CD15/ ELFT protein |
ORF Viral Vector | pGMLPm005170 | mouse Fut4 Lentivirus plasmid |
ORF Viral Vector | vGMLPm005170 | mouse Fut4 Lentivirus particle |
Target information
Target ID | GM-IP0027 |
Target Name | CD15 |
Gene ID | 2526,14345,60670,698078,100682680,101086174,282854,100067105 |
Gene Symbol and Synonyms | CD15,ELFT,FAL,FCT3A,FUC-TIV,Fuct,FucT-IV,FUT4,FUTIV,LeX,SSEA-1,Ssea1 |
Uniprot Accession | P22083,Q62994,Q8HZR3 |
Uniprot Entry Name | FUT4_HUMAN,FUT4_RAT,FUT4_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target, INN Index |
Disease | Cancer |
Gene Ensembl | ENSG00000196371 |
Target Classification | Tumor-associated antigen (TAA) |
The target: CD15, gene name: FUT4, also named as CD15, ELFT, FCT3A, FUC-TIV, FUTIV, LeX, SSEA-1. The product of this gene transfers fucose to N-acetyllactosamine polysaccharides to generate fucosylated carbohydrate structures. It catalyzes the synthesis of the non-sialylated antigen, Lewis x (CD15). [provided by RefSeq, Jan 2009].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.